Slide 1: Supriya Lifescience Ltd. Investor Presentation Q2 FY26
SUPRIYA LIFESCIENCE LTD. Investor Presentation | Q2 FY26
Slide 2: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Supriya Lifescience Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 3: Q2 FY26 Highlights
Q2 FY26 Highlights
Slide 4: Q2 FY26 Highlights and Regional Performance
Q2 FY26 Highlights Revenue EBITDA PBT PAT Quarterly INR 1,998.3 Mn INR 726.5 Mn INR 683.2 Mn INR 504.3 Mn 20% YoY 12% YoY 10% YoY 9% YoY Business Mix Revenue Contribution – By Region Regional Performance 41% 38% 37% 32% 32% 34% Q2 FY25 19% 17% 21% Q1 FY26 6% 6% Q2 FY26 5% 4% 3% 5% Asia Europe LATAM
Slide 5: H1 FY26 Highlights and Regional Performance
H1 FY26 Highlights Revenue EBITDA PBT PAT Quarterly INR 3,449.1 Mn INR 1,243.5 Mn INR 1,157.3 Mn INR 852.2 Mn 6% YoY 2% YoY 5% YoY 6% YoY Business Mix Revenue Contribution – By Region Regional Performance 39% 36% 36% 33% H1 FY25 20% 19% H1 FY26 4% 4% 4% 5% Asia Europe LATAM North America Others 5
Slide 6: Q2 & H1 FY26 - Y-o-Y Highlights
Q2 & H1 FY26 - Y-o-Y Highlights (in INR Mn) Revenue EBITDA PBT PAT 20% YoY 6% YoY 12% YoY 2% YoY 10% YoY 5% YoY 9% YoY 6% YoY 3449.1 1272.6 1243.6 907.9 852.2 3267.3 1218.4 1157.3 1998.3 726.6 683.2 461.5 504.3 1661.0 647.2 620.6 Q2FY25 Q2FY26 H1FY25 H1FY26 Q2FY25 Q2FY26 H1FY25 H1FY26 Q2FY25 Q2FY26
Slide 7: Business Mix Revenue Contribution – By Therapy
Business Mix Revenue Contribution – By Therapy Performance of the Top Therapeutic Areas 54% 46% 12% 11% 12% 10% 8% 6% 7% 5% 4% 2% 3% 2% Anesthetic Analgesic Anti-Histamine Vitamins Anti-Asthmatic Anti-Allergic Anti-hypertensive H1 FY25 H1 FY26 7
Slide 8: Profit & Loss Statement
Profit & Loss Statement Particulars (in INR Mn) Q2 FY26 Q2 FY25 Y-o-Y Q1 FY26 Q-o-Q H1 FY26 H1 FY25 Y-o-Y Revenue from Operations 1,998.3 1,661.0 20.3% 1,450.7 37.7% 3,449.1 3,267.3 5.6% Cost of Goods Sold 557.3 459.8 21.2% 317.7 75.4% 875.0 945.7 -7.5% Employee Benefits Expense 244.8 196.9 24.4% 22
Slide 9: Balance Sheet
Balance Sheet Assets Mar 25 Sep 25 Equity and Liabilities Mar 25 Sep 25 Non-current assets Equity (i) Property, plant and equipment 4,468 4,519 (i) Equity share capital 161 161 (ii) Right to Use Asset 46 44 (ii) Other equity 9,807 10,657 (iii)Capital Work in progress 1,480 1,725 Total Equity 9,968 1
Slide 10: Company Overview
Company Overview
Slide 11: Business Overview
Business Overview Global leader in Anti-histamines, Anti-Allergic, Vitamins, Anti-Asthamatics & Anesthetics 40+ APIs 120+ Countries 35,000 Sq.mts 932 KLPD Niche product basket Diversified operations with presence Manufacturing facility spread across Reactor capacity WHO-GMP, Written Confirmation, IS
Slide 12: Journey So Far
Journey So Far 2020 2021 2022 2023 2024 Third time CEP granted for Pentoxifylline, Esketamine CEP (Certificate of The Company commenced ANVISA Approval USFDA approval Hydrochloride and Salbutamol Sulphate; suitability ) renewed for operations at its Granted NMPA approval granted; Health Canada Pheni
Slide 13: Backward Integrated Business Model
Backward Integrated Business Model Cost-competitive Supply Security Low Price Risk In-House Processes Structure Steady supply of essential raw Protection against market Less Dependence On External Increasing margins materials fluctuations Parties 18 products are backward integrated* in following the
Slide 14: Diversified Geographic Presence
Diversified Geographic Presence Launches New Therapies • Contrast Media • Cardio Vascular • ADHD New Products Launched new product to further strengthen the Anesthetic therapy Presence in 120+ portfolio Countries Across Globe 14
Slide 15: Diversified Revenues with Extensive Global Presence
Diversified Revenues with Extensive Global Presence Significant export presence, with low dependence on a … with balanced customer concentration specific geography Export sales, as a % of revenue from operations Share of top 10 customers, as a % of revenue from operations 85% 58% 47% 45% 49% 80% 79%
Slide 16: Advanced Manufacturing
Advanced Manufacturing o Well defined areas for R&D, Quality Control (chemical, microbiology), Quality Assurance, dedicated areas for engineering maintenance, 5 9 warehouse, raw materials, packaging materials and Manufacturing Blocks Clean Rooms finished goods stores o Recently commissioned Effluent
Slide 17: R&D Capabilities
R&D Capabilities Supported by R&D driven mindset DSIR approved facility • A team of 60+ scientists primarily focused on API process development across the value chain • Already started two R&D centres – 4* Process Patent o Ambernath R&D – Formulations and Generic APIs Filed in India o Lote R&D – Lif
Slide 18: CMO Capabilities
CMO Capabilities • State-of-the-art, GMP compliant manufacturing facility along with pilot facility for scale up available for trials before validation • Complete support in validation, stability, & compilation of dossiers • Dedicated technology transfer team is periodically trained to enhance skill
Slide 19: Recently Commissioned state-of-the-art E Block
Recently Commissioned state-of-the-art E Block • Capacity: 335 KLPD • Large volume equipment – multipurpose synthesis with focus on backward integration capabilities • Closed systems using gravity flow equipped with process control system. 19
Slide 20: FDF Facility ready for commissioning at Ambernath
FDF Facility ready for commissioning at Ambernath • The site spans 5,000 sqm, with 70% of the area constructed, Facility located at Plot No. N-60, Additional Ambernath MIDC, District Location Thane, Maharashtra, • Situated 60 km from Nhava Sheva Port (New Mumbai) and 50 km from Mumbai International
Slide 21: Complex Chemistries & Reaction (1/2)
Complex Chemistries & Reaction (1/2) Focus on uniform manufacturing standards to achieve standardised product quality across markets … across varied class of reactions Ability to handle complex chemistries.. High vacuum distillations • Cyclisation Grignard reaction Simple to highly complex chiral mo
Slide 22: Complex Chemistries & Reaction (2/2)
Complex Chemistries & Reaction (2/2) Focus on uniform manufacturing standards to achieve standardised product quality across markets … across varied class of reactions Ability to handle complex chemistries.. Chiral molecules synthesis using Chiral auxiliary • Contrast media API synthesis Amidation v
Slide 23: Regulatory Achievements
Regulatory Achievements Strong focus on compliance guided by ethical approach • Our motto is to consistently meet the stringent requirements of regulatory bodies • Supported by a skilled team of regulatory affairs experts dedicated to the timely submission of dossiers and managing regulatory queries
Slide 24: Awards & Accreditation
Awards & Accreditation 2016 2017 2019 • Export House for the Year for 2015-16 awarded by • Export House for the Year for 2016-17 awarded by • Outstanding Export Performance Award for the year Directorate of Directorate of Industries, Government of Maharashtra 2018-19 for product group API / Bulk Dru
Slide 25: Key Management Team
Key Management Team Satish Wagh Executive Chairman & WTD • An honorary Ph.D. in entrepreneurship from Faculty of Management Studies, National American University. • B.Sc. from R.D National College and W.A. Science College, University of Bombay. • Director on the board of Supriya Medi-Chem Private Li
Slide 26: EHS
EHS Environment Health Safety • Regular and strict monitoring to produce highest • Clean, safe and healthy working environment for our • Committed to safe and accident-free operations in all efficiency in pollution control all employees our establishments • Safeguarding our employees and facilities
Slide 27: CSR & Social Work
CSR & Social Work We believe true corporate citizenship is rooted in giving back to society, recognizing our responsibility extends beyond business paradigm • Regular activities hosted in the head office and factory for donations of utilities, clothes, school supplies from the employees to the stude
Slide 28: Historical Financial Performance
Historical Financial Performance
Slide 29: Consistent & Strong Financial Performance
Consistent & Strong Financial Performance (in INR Mn) Robust revenue growth Capex Spend … and, focus on profitability 15.5% 1,623 2,608 1,457 2,140 6,965 1,732 1,880 1,880 949 1,078 1,518 5,301 5,703 1,236 1,289 1,191 3,912 4,609 899 94 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY2
Slide 30: Working Capital Break-up
Working Capital Break-up Inventory Receivables 233 73 206 71 72 198 172 165 63 61 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 Payables Net Working Capital 113 112 235 194 196 75 158 59 124 49 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 30
Slide 31: Future Outlook
Future Outlook
Slide 32: Future Outlook
Future Outlook Two new R&D centres CMO/CDMO space • The future of the company is deeply rooted in R&D, with significant progress made to • Company understands large scale special chemical manufacturing and has experience in enhance research capabilities handling hazardous complex process chemistry 1
Slide 33: Thank You
Supriya Lifescience Limited CIN: L51900MH2008PLC180452 Mr. Krishna Raghunathan - Chief Financial Officer cfo@supriyalifescience.com www.supriyalifescience.com Ernst & Young LLP Runjhun Jain Sneha Salian +91 98207 20993 +91 98194 30437 runjhun.jain1@in.ey.com sneha2.salian@in.ey.com THANK YOU